HK Stock Market Move | CSPC PHARMA (01093) up by over 4% again, Surufatinib Monoclonal Antibody Injection III clinical trial achieves top-line analysis data

CSPC PHARMA (01093) rose more than 4%, as of the time of writing, it increased by 4.37% to 8.36 Hong Kong dollars, with a trading volume of 579 million Hong Kong dollars. On the news front, on December 18, CSPC PHARMA announced that its subsidiary CSPC PHARMA Jiushi Biopharmaceutical Co., Ltd. has obtained topline analysis data from the phase III clinical trial for the equivalent treatment of moderate to severe plaque psoriasis with the injection of Siltuximab. This product is a fully human IgG1 monoclonal antibody drug developed by the group, which is a biosimilar drug to Siltuximab injection (Silute). Silute has been approved in China for the treatment of plaque psoriasis in patients aged 6 and above, psoriatic arthritis, ankylosing spondylitis, and pyogenic hidradenitis, and its efficacy and safety have been widely recognized. The key study has achieved its predetermined primary endpoint and obtained positive topline results. Statistical analysis shows that the product is clinically equivalent to Silute with good safety profile, without any new or unexpected safety signals, and is expected to meet the safety requirements for long-term use in patients. Detailed data from this study will be published in upcoming academic conferences and journals.